Literature DB >> 21584735

[Heterotopic ossifications in total hip arthroplasty: prophylaxis and therapy].

J Schauwecker1, F Pohlig, A Toepfer, H Gollwitzer, R von Eisenhart-Rothe.   

Abstract

Heterotopic ossification (HO) is a frequent and occasionally severe complication after total hip arthroplasty. Clinical symptoms of this benign abnormal bone formation are loss of mobility and local pain. The etiology and pathomechanisms are not yet completely understood. Overexpression of bone morphogenetic proteins and dysregulation of prostaglandin metabolism seem to be relevant. Medication with non-steroidal anti-inflammatory drugs (NSAIDs) and perioperative single dose radiotherapy are used for prophylaxis, whereby radiotherapy should only be performed in patients with a history of HO or additionally after resection of HO. From currently available data selective cyclooxygenase-2 inhibitors seem to have a preventive efficacy equal to the classical NSAIDs diclofenac and indometacin. This work discusses current knowledge about the pathophysiology, risk factors and the clinical approach for prevention and treatment of HO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21584735     DOI: 10.1007/s00132-011-1759-9

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  36 in total

Review 1.  Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty.

Authors:  M Fransen; B Neal
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 2.  Prostaglandin E(2) receptors in bone formation.

Authors:  M Li; D D Thompson; V M Paralkar
Journal:  Int Orthop       Date:  2007-06-26       Impact factor: 3.075

3.  Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement.

Authors:  O Kölbl; D Knelles; T Barthel; U Kraus; M Flentje; J Eulert
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

Review 4.  Heterotopic ossification: a review.

Authors:  Luc Vanden Bossche; Guy Vanderstraeten
Journal:  J Rehabil Med       Date:  2005-05       Impact factor: 2.912

5.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

6.  Heterotopic ossification in total hip arthroplasty. The influence of the approach.

Authors:  V S Pai
Journal:  J Arthroplasty       Date:  1994-04       Impact factor: 4.757

7.  Does indomethacin reduce heterotopic bone formation after operations for acetabular fractures? A prospective randomised study.

Authors:  J M Matta; K A Siebenrock
Journal:  J Bone Joint Surg Br       Date:  1997-11

8.  Determinants of heterotopic ossification after total hip replacement surgery.

Authors:  Marlene Fransen; Bruce Neal; Ian D Cameron; Ross Crawford; Garnet Tregonning; Julie Winstanley; Robyn Norton
Journal:  Hip Int       Date:  2009 Jan-Mar       Impact factor: 2.135

9.  Heterotopic ossification after surface replacement arthroplasty and total hip arthroplasty: a randomized study.

Authors:  Krishna Reddi Boddu Siva Rama; Pascal-André Vendittoli; Muthu Ganapathi; Rene Borgmann; Alain Roy; Martin Lavigne
Journal:  J Arthroplasty       Date:  2008-04-11       Impact factor: 4.757

Review 10.  Periarticular heterotopic ossification after total hip arthroplasty. Risk factors and consequences.

Authors:  L Ahrengart
Journal:  Clin Orthop Relat Res       Date:  1991-02       Impact factor: 4.176

View more
  2 in total

1.  BMP-2 Dependent Increase of Soft Tissue Density in Arthrofibrotic TKA.

Authors:  Tilman Pfitzner; Eric Röhner; Veit Krenn; Carsten Perka; Georg Matziolis
Journal:  Open Orthop J       Date:  2012-05-16

2.  Hybrid SPECT/CT for the assessment of a painful hip after uncemented total hip arthroplasty.

Authors:  Oliver Dobrindt; Holger Amthauer; Alexander Krueger; Juri Ruf; Heiko Wissel; Oliver S Grosser; Max Seidensticker; Christoph H Lohmann
Journal:  BMC Med Imaging       Date:  2015-06-02       Impact factor: 1.930

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.